Abstract: A pharmaceutical composition comprising a benzoyl urea compound having the formula: ##STR1## wherein X is a halogen atom or a nitro group, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, Z.sub.1 is a halogen atom or a trifluoromethyl group, Z.sub.2 is a hydrogen atom or a halogen atom, and A is a .dbd.CH--group or a nitrogen atom, and a nonionic surfactant.

Abstract: The present invention provides (a) an activator for osteoblast comprising, as an active ingredient, a salt between (1) an organogermanium compound represented by the formula (I) ##STR1## [in the above formula (I), R.sub.1, R.sub.2 and R.sub.3 which may be the same or different, are independently a hydrogen atom, a lower alkyl group such as methyl, ethyl or the like, or an aryl group] and (2) a basic group-containing compound, and (b) a method for activating osteoblasts, which comprises administering in need of such treatment an effective amount of a salt between an organogermanium compound represented by the above formula (I) and a basic group-containing compound.

Abstract: Pharmaceutical compounds and compositions for injectable use in the treatment of thromboxane A.sub.2 mediating diseases, comprising a pharmaceutical carrier and a pharmacologically effective amount of a compound of the formula: ##STR1## wherein R.sup.1 is carboxyl or 5-tetrazolyl; R.sup.2 is hydrogen, methyl, hydroxy, chloro, or bromo; or a pharmaceutically acceptable ester or salt thereof, together with one or more non-toxic pharmaceutically acceptable carriers; and methods for treating thromboxane A.sub.2 mediating diseases.

Abstract: Novel catecholamine solutions for physiological uses are provided at a pH in the range of 1.0-5.0, comprising catecholamine, acetylcysteine, chelating agent and buffering agents. The compositions are stabilized from oxidation without the use of sulfites and are preferably administered by inhalation.

Abstract: The present invention relates to specific ligands for estrogen or progestagen steroid hormone receptors which have the formula ##STR1## in which X denotes a vinyl group substituted by a radioactive or nonradioactive halogen on the double bond according to a Z isomerism, andY denotes either a hydroxyl group, in which case the ring to which it is attached is an aromatic ring, or a ketone functional group, in which case it is conjugated with a double bond at C.sub.4 -C.sub.5.An application of the ligands according to the invention is the targeted therapy and/or medical imagery, especially of cancer. However, these ligands can also be employed in the quantitative determination of said hormone receptors.However, the labeled ligands according to the invention are of very particular interest in the case of the targeted radiotherapy of cancer.

Abstract: An agent for relieving radiogenic or drug-induced side effects, characterized by comprising a spergualin derivative of the following formula (I):NH.sub.2 --C(.dbd.NH)--NH--R.sub.1 --R.sub.2 --CONH--R.sub.3 --CONH--(CH.sub.2).sub.4 --NH--(CH.sub.2).sub.3 --NH--Xwherein R.sub.1 represents --(CH.sub.2).sub.4 --, --(CH.sub.2).sub.6 ##STR1## R.sub.2 represents --(CH.sub.2).sub.2 -- or --CH.dbd.CH--, R.sub.3 represents --(CH(OH)--CH(OMe)--, --CH.sub.2 -- or --(CH.sub.2).sub.m --CH(OH)--(CH.sub.2).sub.n -- (m represent an integer of 0,1 or 2 and n represents an integer of 1 or 2)X represents a hydrogen atom or a group formed by removing a hydroxyl group from a carboxyl group of an amino acid,or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: Phenylethanolamine analog active compounds, optionally substituted on the phenyl group with an halogen atom or with an alkyl or trifluoromethyl group and substituted on the amino group with a phenylalkyl or phenoxy alkyl group optionally substituted on the benzene ring, are used for the treatment and/or prophylaxis of gastrointestinal diseases associated with a smooth muscle contraction.

Abstract: N-[2-(2-oxo-1-imidazolidinyl)ethyl]-3-phenylurea and analogs are useful for protecting against oxygen-derived free radical damage in mammals, by inducing endogenous antioxidant enzymes, including superoxide dismutase, in mammals.

Abstract: The invention encompasses mixtures of antimicrobial agents coencapsulated in liposomes which when administered in vivo exert an enhanced therapeutic effect. The therapeutic effectiveness of the coencapsulated antimocrobial agents is greater than that of the same combination administered either in solution or as a mixture of liposome populations each containing one of the antimicrobial agents.

Abstract: A method for treating shock in a patient, which comprises administering to the patient a therapeutically effective amount of a diazepinone of the general formula: ##STR1## wherein A represents a 5,11-dihydro-6H-pyrido[2,3-b] [1,4] benzodiazepin-6-one group bound in the 11-position; a 5,10-dihydro-11H-dibenzo [b,e] [1,4] diazepin-11-one group bound in the 5-position; a 5,11-dihydro-10H-pyrido [3-2b] [1-4] benzodiazepin-10-one group bound in the 5-position; a 4,9-dihydro-10H-thieno [3,4-b] [1,5] benzodiazpin-10-one group bound in the 4-position, unsubstituted or substituted at the 1- or 3-position or both in the 1- and 3-position by an alkyl group having from 1 to 4 carbon atoms, or in the 3-positionby chlorine, fluorine or bromine; a 6-11-dihydro-5H-pyrido [2,3-b] [1,5] benzodiazepin-5-one group bound in the 11-position; or a 1-methyl-1,4,9,10-tetrahydropyrrolo-[3,2-b] [1,5] benzodiazepin-10-one group bound in the 4-position, unsubstituted or substituted at the 3-position by methyl or methyl or chlorine;R.sub.

Abstract: A composition for embolization of blood vessels contains the following ingredients in weight percent:______________________________________ particles of an embolizing material from 0.01 to 15.0 polyalkyleneoxide from 0.02 to 0.2 fluid medium the balance. ______________________________________The composition can be used in surgery for reducing blood supply of individual organs, preventing haemorrhage, producing ischemia of malignant tumors and many other cases.

Abstract: Psoralen compositions for extracorporeal administration to blood prior to reinfusion into a subject comprising a sterile aqueous solution of about 0.005 to about 1 mg/ml of a psoralen ethyl alcohol, propylene glycol and water and having a pH from about 2.0 to about 6.0 are disclosed. These compositions are useful for the therapy of a subject being treated by ultraviolet-A photophoresis.

Abstract: Cockroaches can be effectively eliminated or expelled by introducing ozone into a closed space where the cockroaches are expected to inhabit so as to expose an roach-aggregation pheromone contained in cockroach feces to the ozone at a sufficient concentration, to thereby denature the aggregation pheromone to a roach-repellent substance.

Abstract: A composition which has bacteriocidal or bacteriostatic properties which comprises humic acid or a salt or a derivative thereof as active ingredient in a suitable carrier. The active ingredient is preferably an alkali metal salt of humic acid and the carrier is preferably water.

Abstract: Compositions useful in the treatment of disturbances of appetite, disturbances of mood, or both, nicotine withdrawal associated as well as experienced by individuals after discontinuing tobacco use as methods of use therefor. The compositions include serotoninergic drugs, such as d-fenfluramine and fluoxetine.

Abstract: Disclosed herein are analgesic copper coordination compounds and a process for using them in the treatment of analgesia in animal bodies. The copper coordination compounds utilized are the reaction products of copper salts with:1. carboxylic acids or their alkaline earth salts;2. aromatic carboxylic acids or their alkaline earth salts;3. heterocyclic carboxylic acids or their alkaline earth salts;4. amino acids or their alkaline earth salts;5. anthranilic acids or their alkaline earth salts;6. salicyclic acids or their alkaline earth salts;7. acetylsalicylates or their alkaline earth salts;8. arylacetic acids or their alkaline earth salts;9. disubstituted aminodithiocarbamates, and mixtures of any of the above.The process disclosed comprises administering to animals, orally or parenterally, in controlled dosages, the aforementioned copper coordination compounds.

Abstract: There are disclosed novel pharmaceutical compositions which comprise diclofenac or a salt thereof, a penetration agent such as 1-n-dodecylazacycloheptan-2-one or dimethyllauroylamide and, as vehicle, a mineral oil. These compositions have excellent skin penetration properties and can therefore be used in transdermal therapeutic systems (TTS) as drug reservoir.

Abstract: Pharmaceutical compositions comprising tetrahydrocortisol and method of using same in the control of intraocular pressure are disclosed.

Abstract: This invention relates to a novel method for detecting cholesterol which is deposited in the bodies of mammals, which method comprises the steps of administering to a host an effective amount of a photosensitizer of at least one member selected from the group consisting of tetrapyrrole carboxylic acids, corresponding di- or tetrahydropyrrole carboxylic acids, mono-, di- or polyamides of said tetrapyrrole carboxylic acids with amino-mono- or dicarboxylic acids, and salts of the above compounds; applying light of sufficient wavelength to the area of said mammal to be examined; and observing the fluorescence emitted from the area in which cholesterol is deposited.

Abstract: The concentration of endogenous growth hormone in the bloodstream of an economic mammal is increased by the simultaneous administration of an estrogen and a growth hormone releasing factor.